Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by STALICLA
Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor
September 19, 2024
From
STALICLA
Via
GlobeNewswire
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
July 09, 2024
From
STALICLA
Via
GlobeNewswire
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
June 27, 2024
From
STALICLA
Via
GlobeNewswire
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
May 02, 2024
From
STALICLA
Via
GlobeNewswire
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
January 16, 2024
From
STALICLA
Via
GlobeNewswire
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
March 27, 2023
From
STALICLA
Via
GlobeNewswire
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
March 08, 2023
From
STALICLA
Via
GlobeNewswire
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
January 09, 2023
From
STALICLA
Via
GlobeNewswire
STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Project
July 19, 2022
From
STALICLA
Via
Business Wire
STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder
March 24, 2022
From
STALICLA
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.